Bonesupport Holding AB Stock

Equities

BONEX

SE0009858152

Pharmaceuticals

Real-time Estimate Cboe Europe 04:22:18 2024-05-14 am EDT 5-day change 1st Jan Change
232.7 SEK +1.17% Intraday chart for Bonesupport Holding AB +2.56% +23.38%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 857M 78.97M Sales 2025 * 1.19B 110M Capitalization 15.12B 1.39B
Net income 2024 * 174M 16.04M Net income 2025 * 311M 28.66M EV / Sales 2024 * 17.4 x
Net cash position 2024 * 239M 22.03M Net cash position 2025 * 488M 44.98M EV / Sales 2025 * 12.3 x
P/E ratio 2024 *
88.5 x
P/E ratio 2025 *
48.4 x
Employees 118
Yield 2024 *
-
Yield 2025 *
0.43%
Free-Float 89.12%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.17%
1 week+2.56%
Current month+2.74%
1 month-3.73%
3 months+12.94%
6 months+46.04%
Current year+23.38%
More quotes
1 week
224.00
Extreme 224
233.80
1 month
216.20
Extreme 216.2
255.00
Current year
172.50
Extreme 172.5
255.00
1 year
108.40
Extreme 108.4
255.00
3 years
34.20
Extreme 34.2
255.00
5 years
19.05
Extreme 19.05
255.00
10 years
9.04
Extreme 9.04
255.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 18-02-28
Director of Finance/CFO 61 18-10-31
Chief Operating Officer - 21-11-30
Members of the board TitleAgeSince
Director/Board Member 66 -
Chairman 69 17-02-28
Director/Board Member 68 16-08-31
More insiders
Date Price Change Volume
24-05-14 232.6 +1.13% 31 542
24-05-13 230 -0.43% 197,073
24-05-10 231 0.00% 101,177
24-05-08 231 +2.03% 116,012
24-05-07 226.4 -0.96% 83,657

Delayed Quote Nasdaq Stockholm, May 14, 2024 at 04:06 am EDT

More quotes
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
230 SEK
Average target price
292.7 SEK
Spread / Average Target
+27.25%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW